Adrenocortical Carcinoma Market Report 2026

The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.76 billion in 2025 to $3.92 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to limited awareness of acc symptoms, reliance on traditional surgery methods, low prevalence leading to minimal research funding, lack of specialized treatment centers, increasing diagnosis through imaging technologies.

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to advancements in targeted therapies, rise in minimally invasive and laparoscopic procedures, expansion of specialized cancer research institutes, increasing patient awareness and early detection, growing adoption of combination therapy protocols. Major trends in the forecast period include increasing focus on early diagnosis and screening techniques, rising adoption of minimally invasive surgical procedures, expansion of targeted and adjuvant therapies, growing awareness of hormonal imbalance symptoms, enhanced cancer research on localized and metastatic acc.

The rising prevalence of rare cancers is expected to drive the growth of the adrenocortical carcinoma market going forward. Rare cancers are defined by their low incidence rates and significant impact on patient outcomes, often requiring specialized approaches for diagnosis and treatment. The increase in prevalence of rare cancers is influenced by factors such as advances in diagnostic technologies, which have improved the detection of adrenocortical carcinoma, enabling earlier identification of cases that might previously have gone undiagnosed. Adrenocortical carcinoma (ACC) contributes to the growing prevalence of rare cancers as a relatively uncommon but aggressive cancer type, underscoring the need for enhanced diagnostic and therapeutic strategies. For instance, in February 2024, according to a report by the International Agency for Research on Cancer of the World Health Organization, a Switzerland-based intergovernmental organization, rare cancers are defined as those with fewer than six new cases per 100,000 people annually. Collectively, rare cancers account for approximately 25% of all cancer diagnoses. Therefore, the rising prevalence of rare cancers is driving the growth of the adrenocortical carcinoma market.

Major companies operating in the adrenocortical carcinoma market are focusing on developing innovative therapies, such as small-molecule drugs, to target specific tumor pathways and improve patient outcomes. Small-molecule drugs are low molecular weight compounds capable of penetrating cells to modulate proteins or enzymes, regulating biological processes and treating diseases like adrenocortical carcinoma by inhibiting tumor growth pathways. For instance, in January 2023, Orphagen Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, aimed at treating pediatric adrenocortical carcinoma (ACC). This therapy targets pediatric ACC, a rare and aggressive cancer primarily affecting children. The condition often presents with symptoms related to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis typically involves imaging and hormonal evaluations, with prognosis depending on factors like age at diagnosis and tumor resectability.

In October 2024, Esteve Pharmaceuticals, S.A., a Spain-based pharmaceutical company, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed sum. Through this acquisition, Esteve Pharmaceuticals aims to expand its rare disease treatment portfolio, accelerate global growth, enhance patient care, and increase market reach. HRA Pharma Rare Diseases is a France-based pharmaceutical company specializing in therapies for rare diseases, including adrenocortical carcinoma.

Major companies operating in the adrenocortical carcinoma market are HRA Pharma S.A., Servier Laboratories, Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Sanofi S.A., Ipsen S.A., Exelixis Inc., Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc., Pfizer Inc, Novartis AG, Bayer AG, Takeda Pharmaceutical Company, Astellas Pharma Inc., Johnson & Johnson, Gilead Sciences.

North America was the largest region in the adrenocortical carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenocortical carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adrenocortical carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the adrenocortical carcinoma market by raising costs of imported surgical instruments, chemotherapy drugs, and radiation therapy equipment. Segments such as targeted therapy and laparoscopic surgery are most affected, with north america, europe, and asia-pacific regions facing increased procurement costs. This has led to higher treatment expenses and potential delays in therapy adoption. On the positive side, tariffs have encouraged local manufacturing of medical devices and therapies, fostering regional innovation and self-sufficiency in ACC treatment solutions.

The adrenocortical carcinoma market research report is one of a series of new reports that provides adrenocortical carcinoma market statistics, including adrenocortical carcinoma industry global market size, regional shares, competitors with a adrenocortical carcinoma market share, detailed adrenocortical carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. This adrenocortical carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer that develops in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs located above each kidney that produce hormones essential for regulating metabolism, immune function, blood pressure, and the body’s response to stress. Adrenocortical carcinoma (ACC) can disrupt hormone balance, causing symptoms such as weight gain, high blood pressure, or virilization (development of excess male characteristics).

The main types of adrenocortical carcinoma are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma. Localized adrenocortical carcinoma is an aggressive cancer that begins in the adrenal gland and remains confined to it without spreading to other parts of the body. These types are managed using various therapeutic approaches, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The primary end users of these treatments include hospitals and clinics, ambulatory surgical centers, and cancer research institutes.

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.